
Chinese General Practice ›› 2023, Vol. 26 ›› Issue (24): 2997-3004.DOI: 10.12114/j.issn.1007-9572.2023.0029
Special Issue: 男性健康最新文章合辑; 运动相关研究最新文章合辑
• Original Research • Previous Articles Next Articles
Received:2022-12-19
Revised:2023-03-16
Published:2023-08-20
Online:2023-04-03
Contact:
SUN Lixia
通讯作者:
孙丽霞
作者简介:基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0029
| 变量 | 总人群(N=924) | Q1组(n=220) | Q2组(n=240) | Q3组(n=230) | Q4组(n=234) | 检验统计量值 | P值 |
|---|---|---|---|---|---|---|---|
| 一般情况 | |||||||
| 年龄( | 36.9±7.7 | 34.9±7.8 | 35.4±7.4 | 37.2±7.2a | 40.1±7.3abc | 23.26d | <0.01 |
| 高脂血症〔例(%)〕 | 361(39.07) | 49(22.27) | 85(35.42) | 105(45.65) | 122(52.14)abc | 48.39 | <0.01 |
| 高血压〔例(%)〕 | 318(34.42) | 59(26.82) | 62(25.83) | 80(34.78) | 117(50.00)abc | 38.65 | <0.01 |
| 降压药史〔例(%)〕 | 92(9.96) | 11(5.00) | 16(6.67) | 23(10.00) | 42(17.95)abc | 25.60 | <0.01 |
| 饮酒史〔例(%)〕 | 519(56.17) | 117(53.18) | 126(52.50) | 135(58.70) | 141(60.26) | 4.29 | 0.23 |
| 吸烟史〔例(%)〕 | 566(61.26) | 143(65.00) | 146(60.83) | 143(62.17) | 134(57.26) | 2.97 | 0.40 |
| 体育锻炼〔例(%)〕 | 344(37.23) | 84(38.18) | 87(36.25) | 97(42.17) | 76(32.48) | 4.85 | 0.18 |
| 人体测量学指标 | |||||||
| 体质量( | 76.26±12.32 | 75.51±11.94 | 76.05±12.47 | 76.10±13.08 | 77.33±11.76 | 0.90d | 0.44 |
| BMI( | 26.29±3.85 | 25.93±3.80 | 26.08±3.83 | 26.31±4.21 | 26.83±3.50 | 2.42d | 0.06 |
| 腰围( | 89.66±9.68 | 89.18±9.46 | 88.91±9.68 | 89.36±10.43 | 91.16±9.02 | 2.61d | 0.05 |
| SBP( | 134±14 | 133±12 | 132±15 | 135±14 | 137±14ab | 6.42d | <0.01 |
| DBP( | 85±12 | 84±12 | 84±12 | 85±13 | 88±10ab | 7.45d | <0.01 |
| 生化检测指标 | |||||||
| 空腹血糖〔M(P25,P75),mmol/L〕 | 5.40(5.00,5.82) | 4.74(4.50,4.88) | 5.20(5.10,5.30)a | 5.57(5.50,5.69)ab | 6.22(5.99,6.59)abc | 374.54e | <0.01 |
| hs-CRP〔M(P25,P75),mg/L〕 | 0.24(0.01,1.40) | 1.19(0.30,2.60) | 0.25(0.01,1.70)a | 0.16(0.01,1.10)a | 0.11(0.01,0.36)ab | 115.97e | <0.01 |
| 三酰甘油〔M(P25,P75),mmol/L〕 | 1.23(0.83,1.95) | 1.00(0.75,1.59) | 1.19(0.80,1.84) | 1.32(0.84,2.12)a | 1.34(1.00,2.13)a | 23.33e | <0.01 |
| 总胆固醇( | 4.79±1.10 | 4.55±0.96 | 4.64±1.00 | 4.99±1.32ab | 4.96±1.03ab | 9.52d | <0.01 |
| HDL-C( | 1.40±0.35 | 1.45±0.40 | 1.42±0.37 | 1.38±0.33 | 1.35±0.30a | 4.58d | <0.01 |
| LDL-C( | 2.81±0.82 | 2.68±0.76 | 2.76±0.71 | 2.81±0.71 | 2.98±1.05ab | 5.22d | <0.01 |
Table 1 Comparison of epidemiological survey data of the subjects
| 变量 | 总人群(N=924) | Q1组(n=220) | Q2组(n=240) | Q3组(n=230) | Q4组(n=234) | 检验统计量值 | P值 |
|---|---|---|---|---|---|---|---|
| 一般情况 | |||||||
| 年龄( | 36.9±7.7 | 34.9±7.8 | 35.4±7.4 | 37.2±7.2a | 40.1±7.3abc | 23.26d | <0.01 |
| 高脂血症〔例(%)〕 | 361(39.07) | 49(22.27) | 85(35.42) | 105(45.65) | 122(52.14)abc | 48.39 | <0.01 |
| 高血压〔例(%)〕 | 318(34.42) | 59(26.82) | 62(25.83) | 80(34.78) | 117(50.00)abc | 38.65 | <0.01 |
| 降压药史〔例(%)〕 | 92(9.96) | 11(5.00) | 16(6.67) | 23(10.00) | 42(17.95)abc | 25.60 | <0.01 |
| 饮酒史〔例(%)〕 | 519(56.17) | 117(53.18) | 126(52.50) | 135(58.70) | 141(60.26) | 4.29 | 0.23 |
| 吸烟史〔例(%)〕 | 566(61.26) | 143(65.00) | 146(60.83) | 143(62.17) | 134(57.26) | 2.97 | 0.40 |
| 体育锻炼〔例(%)〕 | 344(37.23) | 84(38.18) | 87(36.25) | 97(42.17) | 76(32.48) | 4.85 | 0.18 |
| 人体测量学指标 | |||||||
| 体质量( | 76.26±12.32 | 75.51±11.94 | 76.05±12.47 | 76.10±13.08 | 77.33±11.76 | 0.90d | 0.44 |
| BMI( | 26.29±3.85 | 25.93±3.80 | 26.08±3.83 | 26.31±4.21 | 26.83±3.50 | 2.42d | 0.06 |
| 腰围( | 89.66±9.68 | 89.18±9.46 | 88.91±9.68 | 89.36±10.43 | 91.16±9.02 | 2.61d | 0.05 |
| SBP( | 134±14 | 133±12 | 132±15 | 135±14 | 137±14ab | 6.42d | <0.01 |
| DBP( | 85±12 | 84±12 | 84±12 | 85±13 | 88±10ab | 7.45d | <0.01 |
| 生化检测指标 | |||||||
| 空腹血糖〔M(P25,P75),mmol/L〕 | 5.40(5.00,5.82) | 4.74(4.50,4.88) | 5.20(5.10,5.30)a | 5.57(5.50,5.69)ab | 6.22(5.99,6.59)abc | 374.54e | <0.01 |
| hs-CRP〔M(P25,P75),mg/L〕 | 0.24(0.01,1.40) | 1.19(0.30,2.60) | 0.25(0.01,1.70)a | 0.16(0.01,1.10)a | 0.11(0.01,0.36)ab | 115.97e | <0.01 |
| 三酰甘油〔M(P25,P75),mmol/L〕 | 1.23(0.83,1.95) | 1.00(0.75,1.59) | 1.19(0.80,1.84) | 1.32(0.84,2.12)a | 1.34(1.00,2.13)a | 23.33e | <0.01 |
| 总胆固醇( | 4.79±1.10 | 4.55±0.96 | 4.64±1.00 | 4.99±1.32ab | 4.96±1.03ab | 9.52d | <0.01 |
| HDL-C( | 1.40±0.35 | 1.45±0.40 | 1.42±0.37 | 1.38±0.33 | 1.35±0.30a | 4.58d | <0.01 |
| LDL-C( | 2.81±0.82 | 2.68±0.76 | 2.76±0.71 | 2.81±0.71 | 2.98±1.05ab | 5.22d | <0.01 |
| 变量 | 总人群(N=924) | Q1组(n=220) | Q2组(n=240) | Q3组(n=230) | Q4组(n=234) | F(H)值 | P值 |
|---|---|---|---|---|---|---|---|
| SBP1( | 132±15 | 130±14 | 131±15 | 132±16 | 135±16ab | 4.15 | <0.01 |
| SBP2( | 132±15 | 130±14 | 132±15 | 132±15 | 135±15ab | 6.01 | <0.01 |
| ∆SBP〔M(P25,P75),mmHg〕 | 1(-5,6) | 0(-7,6) | 1(-4,6) | 0(-5,6) | 1(-5,7) | 4.54e | 0.21 |
| DBP1( | 79±11 | 77±11 | 78±11 | 79±11 | 82±10ab | 8.04 | <0.01 |
| DBP2( | 79±11 | 78±11 | 78±11 | 79±11 | 82±10abc | 9.62 | <0.01 |
| ∆DBP〔M(P25,P75),mmHg〕 | 0(-3,4) | 0(-3,4) | 0(-4,5) | 0(-3,4) | 1(-3,5) | 1.86e | 0.60 |
| MAP1( | 99.17±12.50 | 97.23±12.19 | 98.03±12.24 | 99.28±13.03 | 102.04±12.08ab | 6.66 | <0.01 |
| MAP2( | 99.44±11.98 | 97.57±11.14 | 98.74±12.14 | 99.39±12.10 | 101.97±12.10ab | 5.63 | <0.01 |
| ∆MAP〔M(P25,P75),mmHg〕 | 0.30(-4.20,5.10) | 0.80(-3.70,5.40) | 0.30(-3.80,5.50) | -0.05(-4.70,4.30) | -0.15(-4.50,4.90) | 1.70e | 0.64 |
| HR1( | 80±13 | 80±12 | 79±12 | 81±12 | 81±12 | 2.14 | 0.09 |
| HR2( | 86±14d | 85±13d | 85±14d | 85±12d | 87±14 | 1.34 | 0.26 |
| ∆HR〔M(P25,P75),次/min〕 | 5(0,10) | 6(0,11) | 5(0,11) | 4(-1,8) | 5(0,11) | 5.29e | 0.15 |
| baPWV1( | 1 375.98±209.61 | 1 351.63±198.92 | 1 345.50±204.86 | 1 384.63±216.83 | 1 421.65±209.58abc | 6.63 | <0.01 |
| baPWV2( | 1 342.24±208.82d | 1 309.95±194.19d | 1 312.10±208.65d | 1 343.84±203.35d | 1 401.92±215.65abcd | 10.08 | <0.01 |
| ∆baPWV〔M(P25,P75),cm/s〕 | -36.0 (-87.0,24.0) | -45.5 (-93.0,12.5) | -36.5 (-85.0,19.5) | -39.5 (-95.0,18.0) | -23.0 (-77.0,35.0) | 7.51e | 0.06 |
| MET( | 12.16±2.55 | 12.42±2.78 | 12.21±2.26 | 12.22±2.78 | 11.79±2.33 | 2.49 | 0.06 |
| VO2max( | 42.56±8.91 | 43.50±9.71 | 42.73±7.89 | 42.78±9.74 | 41.29±8.14 | 2.49 | 0.06 |
| 峰值HR( | 139.35±14.65 | 139.40±14.90 | 139.25±15.62 | 140.14±13.69 | 138.61±14.33 | 0.43 | 0.73 |
| Time( | 7.13(4.94,11.16) | 7.51(5.41,11.37) | 7.38(4.92,12.61) | 7.03(5.00,11.15) | 6.67(4.73,9.55) | 8.22e | 0.06 |
Table 2 Comparison of baPWV-related data before and after the secondary load test of the power vehicle bicycle
| 变量 | 总人群(N=924) | Q1组(n=220) | Q2组(n=240) | Q3组(n=230) | Q4组(n=234) | F(H)值 | P值 |
|---|---|---|---|---|---|---|---|
| SBP1( | 132±15 | 130±14 | 131±15 | 132±16 | 135±16ab | 4.15 | <0.01 |
| SBP2( | 132±15 | 130±14 | 132±15 | 132±15 | 135±15ab | 6.01 | <0.01 |
| ∆SBP〔M(P25,P75),mmHg〕 | 1(-5,6) | 0(-7,6) | 1(-4,6) | 0(-5,6) | 1(-5,7) | 4.54e | 0.21 |
| DBP1( | 79±11 | 77±11 | 78±11 | 79±11 | 82±10ab | 8.04 | <0.01 |
| DBP2( | 79±11 | 78±11 | 78±11 | 79±11 | 82±10abc | 9.62 | <0.01 |
| ∆DBP〔M(P25,P75),mmHg〕 | 0(-3,4) | 0(-3,4) | 0(-4,5) | 0(-3,4) | 1(-3,5) | 1.86e | 0.60 |
| MAP1( | 99.17±12.50 | 97.23±12.19 | 98.03±12.24 | 99.28±13.03 | 102.04±12.08ab | 6.66 | <0.01 |
| MAP2( | 99.44±11.98 | 97.57±11.14 | 98.74±12.14 | 99.39±12.10 | 101.97±12.10ab | 5.63 | <0.01 |
| ∆MAP〔M(P25,P75),mmHg〕 | 0.30(-4.20,5.10) | 0.80(-3.70,5.40) | 0.30(-3.80,5.50) | -0.05(-4.70,4.30) | -0.15(-4.50,4.90) | 1.70e | 0.64 |
| HR1( | 80±13 | 80±12 | 79±12 | 81±12 | 81±12 | 2.14 | 0.09 |
| HR2( | 86±14d | 85±13d | 85±14d | 85±12d | 87±14 | 1.34 | 0.26 |
| ∆HR〔M(P25,P75),次/min〕 | 5(0,10) | 6(0,11) | 5(0,11) | 4(-1,8) | 5(0,11) | 5.29e | 0.15 |
| baPWV1( | 1 375.98±209.61 | 1 351.63±198.92 | 1 345.50±204.86 | 1 384.63±216.83 | 1 421.65±209.58abc | 6.63 | <0.01 |
| baPWV2( | 1 342.24±208.82d | 1 309.95±194.19d | 1 312.10±208.65d | 1 343.84±203.35d | 1 401.92±215.65abcd | 10.08 | <0.01 |
| ∆baPWV〔M(P25,P75),cm/s〕 | -36.0 (-87.0,24.0) | -45.5 (-93.0,12.5) | -36.5 (-85.0,19.5) | -39.5 (-95.0,18.0) | -23.0 (-77.0,35.0) | 7.51e | 0.06 |
| MET( | 12.16±2.55 | 12.42±2.78 | 12.21±2.26 | 12.22±2.78 | 11.79±2.33 | 2.49 | 0.06 |
| VO2max( | 42.56±8.91 | 43.50±9.71 | 42.73±7.89 | 42.78±9.74 | 41.29±8.14 | 2.49 | 0.06 |
| 峰值HR( | 139.35±14.65 | 139.40±14.90 | 139.25±15.62 | 140.14±13.69 | 138.61±14.33 | 0.43 | 0.73 |
| Time( | 7.13(4.94,11.16) | 7.51(5.41,11.37) | 7.38(4.92,12.61) | 7.03(5.00,11.15) | 6.67(4.73,9.55) | 8.22e | 0.06 |
| 模型 | 自变量 | B(95%CI) | SE | t值 | P值 |
|---|---|---|---|---|---|
| 模型1 | Q4 | ||||
| Q1 | -30.10(-47.39,-12.82) | 8.81 | 6.66 | <0.01 | |
| Q2 | -22.54(-39.48,-5.60) | 8.63 | -2.61 | 0.01 | |
| Q3 | -25.38(-42.39,-8.37) | 8.67 | -2.93 | <0.01 | |
| 模型2 | Q4 | ||||
| Q1 | -18.82(-36.69,-0.94) | 9.11 | -2.07 | 0.04 | |
| Q2 | -12.71(-29.74,4.32) | 8.68 | -1.47 | 0.14 | |
| Q3 | -19.58(-36.45,-2.71) | 8.60 | -2.28 | 0.02 | |
| 模型3 | Q4 | ||||
| Q1 | -18.96(-36.96,-0.96) | 9.17 | -2.07 | 0.04 | |
| Q2 | -12.37(-29.35,4.60) | 8.65 | -1.43 | 0.15 | |
| Q3 | -15.23(-31.95,1.49) | 8.52 | -1.79 | 0.07 |
Table 3 Generalized linear model analysis of the effect of fasting blood glucose level on baPWV before and after the secondary load test of the power vehicle bicycle
| 模型 | 自变量 | B(95%CI) | SE | t值 | P值 |
|---|---|---|---|---|---|
| 模型1 | Q4 | ||||
| Q1 | -30.10(-47.39,-12.82) | 8.81 | 6.66 | <0.01 | |
| Q2 | -22.54(-39.48,-5.60) | 8.63 | -2.61 | 0.01 | |
| Q3 | -25.38(-42.39,-8.37) | 8.67 | -2.93 | <0.01 | |
| 模型2 | Q4 | ||||
| Q1 | -18.82(-36.69,-0.94) | 9.11 | -2.07 | 0.04 | |
| Q2 | -12.71(-29.74,4.32) | 8.68 | -1.47 | 0.14 | |
| Q3 | -19.58(-36.45,-2.71) | 8.60 | -2.28 | 0.02 | |
| 模型3 | Q4 | ||||
| Q1 | -18.96(-36.96,-0.96) | 9.17 | -2.07 | 0.04 | |
| Q2 | -12.37(-29.35,4.60) | 8.65 | -1.43 | 0.15 | |
| Q3 | -15.23(-31.95,1.49) | 8.52 | -1.79 | 0.07 |
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
韩旭,刘倩,马一涵,等. 非糖尿病人群空腹血糖水平对动脉僵硬度进展的影响[J]. 中华高血压杂志,2021,29(1):41-47. DOI:10.16439/j.issn.1673-7245.2021.01.010.
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
体育总局关于开展第五次国民体质监测的通知[EB/OL].(2019-02-02)[2022-08-02].
|
| [23] |
|
| [24] |
|
| [25] |
中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志,2019,24(1):24-56.
|
| [26] |
中国成人血脂异常防治指南制订联合委员会. 中国成人血脂异常防治指南[J]. 中华心血管病杂志,2007,35(5):390-419. DOI:10.3760/j.issn:0253-3758.2007.05.003.
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [1] | LI Jiawei, GAO Xinyi, GE Aoqi, LI Juanjuan, YUAN Beibei. Demand and Associated Factors for Integrated Medical Care and Preventive Services among Patients with Type 2 Diabetes [J]. Chinese General Practice, 2026, 29(21): 3028-3039. |
| [2] | PAN Ziyun, YIN Hao, LIN Zhirou, MAO Jingyi, HUANG Yan, LUO Yanhua, XIAO Jiafu, HU Yin. From Mechanism to Therapy: Diabetic Autonomic Neuropathy [J]. Chinese General Practice, 2026, 29(21): 2982-2988. |
| [3] | AN Yanhong, WANG Shidong, LI Xiaoran, GUO Jiayang, WANG Zhe, SHA Peilin, MENG Yijun, LI Xiaoxuan, SHI Xue, YU Zexing, XIAO Yonghua. Study on Risk Factors and Nomogram Prediction Model for Diabetic Kidney Disease: Based on Contrast-enhanced Ultrasound Technology [J]. Chinese General Practice, 2026, 29(21): 2995-3003. |
| [4] | WANG Yang, ZHAO Shiting, CHEN Yingying, SUN Zilin, QIU Shanhu. Key Points of Exercise Intervention and Implementation for People with Complications of Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(21): 2989-2994. |
| [5] | REYILAI· Maimaiti, ZHOU Yiran, WU Yun, LIU Zhencheng, LU Yaoqin, WU Haiyan. Association between Novel Obesity Indicators and Cardiovascular Disease Risk in Hypertensive Patients [J]. Chinese General Practice, 2026, 29(20): 2836-2845. |
| [6] | GE Dan, WANG Zhi, DING Qun, GUO Tonglan, XU Tongdao. Relationship between Remnant Cholesterol and Non-alcoholic Fatty Liver Disease as well as Progressive Liver Fibrosis in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(20): 2854-2859. |
| [7] | ZHANG Xiaojuan, LIU Yang, PENG Bo, YE Yuan, ZHU Kun. Study on the Prevention and Treatment of Hypertension and Diabetes Mellitus in Community Hospital [J]. Chinese General Practice, 2026, 29(19): 2614-2620. |
| [8] | HU Min, LYU Xiangdong. Accuracy of Artificial Intelligence in Remote Electrocardiography Diagnosis [J]. Chinese General Practice, 2026, 29(18): 2498-2503. |
| [9] | JIAN Yingchun, ZENG Yongqin, ZHANG Haiping, WANG Zhengdi, AN Ke, YAN Rui. Recent Advances in Mitochondrial Dysfunction in Chronic Metabolic Diseases [J]. Chinese General Practice, 2026, 29(18): 2577-2584. |
| [10] | LI Yachan, YANG Yang, XU Qianting, KE Tingyu. Association between the Chinese Visceral Adiposity Index and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(18): 2482-2488. |
| [11] | LI Menglin, DING Fang, QIAN Yu, PU Dong, DU Qianqian, GUAN Tianhang, HE Yilin. Study on Glycemic Control Status and Influencing Factors among Community Diabetic Patients [J]. Chinese General Practice, 2026, 29(17): 2334-2339. |
| [12] | LI Simin, ZHANG Tingting, WANG Kunbo, YANG Jianzhou, PING Weiwei. Effects of Exercise Dosage on Elderly Patients with Sarcopenia: a Meta-analysis [J]. Chinese General Practice, 2026, 29(17): 2400-2409. |
| [13] | FU Mingyuan, YU Xiaoyi, GE Caiying, KONG Min. Impaired Awareness of Hypoglycemia: Prevalence and Determinants among Community-based Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(16): 2252-2258. |
| [14] | WANG Rui, LUO Dan, YANG Cuicui, WENG Xinyi, WANG Yubing, XU Jingjing. Complex Network Analysis of Resilience in Adolescents with Type 1 Diabetes Mellitus Based on Multi-sourced Stigma [J]. Chinese General Practice, 2026, 29(16): 2264-2272. |
| [15] | ZHEN Rui, GU Xufang, GAO Shengwei, ZHANG Bowen, REN Zhenjuan, YANG Ruixuan. Burden of Cardiovascular Diseases Attributable to Metabolic Risk Factors in China 1990—2021 and Projected Trends from 2022 to 2035 [J]. Chinese General Practice, 2026, 29(15): 2077-2083. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||